Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Humanized anti-IL-6R mAb therapy for JIA (1)
3. Regulation of antibody response in vitro
4. Interleukin-6
5. IL-6 transgenic mouse
6. Acute phase responses in IL-6 deficient mice
7. IL-6 and IL-6 receptor interaction
8. Cytokine receptor systems
9. IL-6 signal transduction mechanism
10. NF-IL6 induction of proteins, cytokines & viruses
11. NF-IL6 induces HIV-1 replication
12. Feedback regulation in IL-6 signaling
13. Aberrant production of IL-6 in myxoma cells
14. Synovial fluid IL-6 in Rheumatoid Arthritis patients
15. Anti-IL6R Ab blocks IL-6 binding with the receptor
16. Recombinant anti-human IL-6R mAb
17. Anti-human IL-6R antibody (tocilizumab)
18. Castleman's disease (CD)
19. Features of Castleman's disease
20. Lymph nodes in Castleman's disease
21. KSHV/HHV8 in Castleman's disease
22. Humanized anti IL-6 receptor Ab therapy
23. Therapy of CD by humanized anti-IL-6R Ab
24. Anti-IL-6R Ab improved laboratory abnormalities
25. Rheumatoid Arthritis (RA)
26. RA and IL-6 deficient mice
27. ACR response rate using tocilizumab
28. Tocilizumab therapy: Pre and post radiographs
29. Inhibition of RANK ligand expression
30. Inhibition of TRAP-positive osteoclast formation
31. Disappearance of amyloid deposits in the colon
32. The RADIATE study
33. Juvenile Idiopathic Arthritis (JIA)
34. Humanized anti-IL-6R mAb therapy for JIA (2)
35. Systemic-onset Juvenile Idiopathic Arthritis
36. Decrease in inflammation markers
37. Decrease in fever episodes
38. Physicians' assessment of disease activity
39. Efficacy responses with tocilizumab therapy in JIA
40. Tocilizumab in refractory relapsing polychondritis
41. Treatment of reactive arthritis with tocilizumab
42. Tocilizumab in polymyalgia rheumatica
43. Tocilizumab treatment in systemic sclerosis
44. MR16-1 in mouse model of scleroderma
45. ACR response and serum IL-6 using tocilizumab
46. IL-6 , TH17 and Treg cells
47. Suppression of CII-induced arthritis (CIA)
48. Suppression of IL-17 in MR16-1 treated mice
49. No suppressive on Th17 induction with TNFR-Fc
50. MR16-1 treatment reduces the incidence of EAE
51. MR16-1 suppresses Th17 & Th1 development
52. Experimental autoimmune uveoretinitis (EAU)
53. Th17 development in IL-6 KO mice with EAU
54. IL-17 and IFN-gamma KO mice develop EAU
55. Regulatory T cells are important for inhibiting EAU
56. TNF-alpha, IL-1 and IL-23 do not induce Th17 cells
57. TNF-a, IL-1 & IL-23 don't inhibit Foxp3+ Treg cells
58. Ahr is specifically induced by IL-6 and TGF-beta
59. Ahr: aryl hydrocarbon receptor
60. Induction of IL-17 in Ahr-deficient naive T cells
61. Ahr specifically binds with Stat1 and Stat5
62. Distinct roles of Stat family in Th17 differentiation
63. Ahr gene deletion blocks the CIA development
64. T cell-specific deletion of Ahr ameliorates the CIA
65. Pro-inflammatory cytokines in Ahr KO mice
66. Cytokine production in Ahr KO mice
67. Research group
68. Collaborations

Topics Covered

• IL-6 is a pleiotropic proinflammatory cytokine
• Its overproduction is involved in inflammatory autoimmune diseases including rheumatoid arthritis
• Blocking of IL-6 signals by anti-IL6 receptor antibody (Tocilizumab) shows therapeutic effect on various autoimmune diseases
• Tocilizumab exerts its effect by inhibiting the induction of a helper T cell subset (TH17)
• Aryl-hydrocarbon receptor (Ahr) is one of the essential molecule for the IL-6 mediated induction of TH17 cells

Links

Series:

• Cytokines

Categories:

• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on December 5, 2011

Financial Disclosures

• Prof. Tadamitsu Kishimoto has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.